Chronic kidney disease in patients with diabetes mellitus: new challenges
Authors:
- M. S. ShamkhalovaMSM. S. Shamkhalova
- O. Y. SukharevaOSO. Y. Sukhareva
- S. A. MartynovSMS. A. Martynov
- A. S. SeverinaASA. S. Severina
- O. K. VikulovaOVO. K. Vikulova
- N. P. TrubitsynaNTN. P. Trubitsyna
- O. N. NaumenkoONO. N. Naumenko
- N. V. ZaytsevaNZN. V. Zaytseva
- M. V. ShestakovaMSM. V. Shestakova
- I. I. DedovIDI. I. Dedov
- N. G. MokryshevaNMN. G. Mokrysheva
Open Access
- 24 January 2025
- journal article
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (1) , 46-55
Abstract
Chronic kidney disease (CKD) is a supranosological concept, defined as a disorder of the structure and/or function of the kidneys for 3 months or more that leads to health consequences. CKD develops in 20–40% of patients with diabetes mellitus (DM). Dynamic analysis of epidemiological indicators of CKD in patients with diabetes mellitus points to the prevalence increase of this pathology in the Russian Federation in 2010–2022. Improved quality of diagnostics of earlier stages complications, a decrease in the risk of cardiovascular events (the leading cause of death) and end-stage renal failure at a later age and with a longer duration of diabetes are noted as well. The development of tools for predicting the risk of the pathology progression and its complications has made it possible to improve patient monitoring and routing. Current international and domestic recommendations emphasize a comprehensive approach to the treatment of CKD, including lifestyle modification, evidence-based pharmacological treatments aimed at preserving organ function, and improving cardiovascular prognosis. An optimal model of care for patients with diabetes and CKD, aimed at multidisciplinary care and adapted according to the severity of CKD, will lead to the best outcomes for the individual patient and society.Keywords
This publication has 21 references indexed in Scilit:
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trialDiabetes Research and Clinical Practice, 2023
- Aminoaciduria and metabolic dysregulation during diabetic ketoacidosis: Results from the diabetic kidney alarm (DKA) studyJournal of Diabetes and its Complications, 2022
- Epidemiology of chronic kidney disease: an update 2022Kidney International Supplements, 2022
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2020
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet Diabetes & Endocrinology, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- NoticeKidney International Supplements, 2013